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has opened many new perspectives in endocrine, metabolic, and cardiovascular research areas, suggesting the
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Ghrelin and its synthetic analog hexarelin are specific ligands of growth hormone 
secretagogue (GHS) receptor. GHS have strong growth hormone-releasing effect and other 
neuroendocrine activities such as stimulatory effects on prolactin and adrenocorticotropic 
hormone secretion. Recently, several studies have reported other beneficial functions of GHS 
that are independent of GH. Ghrelin and hexarelin, for examples, have been shown to exert 
GH-independent cardiovascular activity. Hexarelin has been reported to regulate peroxisome 
proliferator-activated receptor gamma (PPAR-γ) in macrophages and adipocytes. PPAR-γ is 
an important regulator of adipogenesis, lipid metabolism, and insulin sensitization. Ghrelin 
also shows protective effects on beta cells against lipotoxicity through activation of 
phosphatidylinositol-3 kinase/protein kinase B, c-Jun N-terminal kinase (JNK) inhibition, and 
nuclear exclusion of forkhead box protein O1. Acylated ghrelin (AG) and unacylated ghrelin 
(UAG) administration reduces glucose levels and increases insulin-producing beta cell 
number, and insulin secretion in pancreatectomized rats and in newborn rats treated with 
streptozotocin, suggesting a possible role of GHS in pancreatic regeneration. Therefore, the 
discovery of GHS has opened many new perspectives in endocrine, metabolic, and 
cardiovascular research areas, suggesting the possible therapeutic application in diabetes and 
diabetic complications especially diabetic cardiomyopathy. Here, we review the 
physiological roles of ghrelin and hexarelin in the protection and regeneration of beta cells 
and their roles in the regulation of insulin release, glucose, and fat metabolism and present 
their potential therapeutic effects in the treatment of diabetes and diabetic-associated heart 
diseases. 
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Diabetes mellitus is one of the leading causes of morbidity and mortality worldwide. 
Currently, about 382 million people suffer from this disease and by 2035, this will rise to 592 
million [1]. Diabetes is classified as type 1 diabetes (T1D), characterized by absolute loss of 
insulin production, and type 2 diabetes (T2D), which is a result of both chronic insulin 
resistance and loss of pancreatic cell mass and function [2]. T2D is the most common form, 
accounting for about 95 % of diabetes [3]. The pathogenesis of T2D involves both genetic 
and environmental factors. Obesity is the most common cause of developing T2D as it 
represents about 75 % of the causes [4]. Obesity can lead to insulin resistance and impairment 
in energy metabolism of most tissues such as skeletal muscles, liver, adipose tissue, and 
pancreatic islets. However, insulin resistance does not lead to T2D unless it is accompanied 
by pancreatic beta cell dysfunction [5–7]. 
 
What are still unknown are the time points when beta cell dysfunction starts and the relative 
contribution of beta cell dysfunction in the development of T2D. Current evidence suggested 
that islet function was about 50 % of normal at the time of diagnosis [8]. The reduction of 
beta cell function most probably starts early about 10–12 years before diagnosis of diabetes 
[9]. The major factors for causing progressive decrease in beta cell structure and function 
during the course of the disease are glucotoxicity, lipotoxicity, proinflammatory cytokines, 
and islet cell amyloidosis [10]. The combined increased flux of free fatty acids and glucose 
into the beta cell has detrimental consequences on beta cells [11]. The excess free fatty acid 
entering beta cells inhibits proper glucose utilization in the mitochondria. Additionally, it is 
reported that these lipids are metabolized in a different way forming lipid intermediates that 
cause abnormal signaling and beta cell dysfunction. The glucotoxicity and lipotoxicity also 
may cause an increase in reactive oxygen species (ROS) which can damage the cell and then 
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lead to beta cell death [12]. The role of the proinflammatory cytokines in causing beta cell 
apoptosis had been demonstrated [13, 14]. Macrophages may infiltrate beta cells when they 
start becoming damaged. This causes cytokine release from the macrophages, which may 
alter the ability of the beta cell to proliferate. Impaired beta cell function and mass could be 
reversible at early stages of the disease [15]. 
 
Insulin and its downstream signaling pathway play important roles in the homeostasis of 
blood levels of glucose, and the disruption of the signaling pathway plays an important role in 
the pathophysiology of T2D. Insulin reduces blood glucose levels through increasing glucose 
uptake in muscle and fat and decreasing hepatic glucose production. Skeletal muscle 
consumes most glucose, accounting for about 75 % of insulin-dependent glucose uptake 
while adipose tissue accounts for only a small fraction [16]. The adipose tissue, however, is 
crucial in the normal regulation of the insulin action all over the body. Adipocytes can store 
excess lipids in obesity but when they become saturated, lipids begin to accumulate inside 
other organs, and tissues making them insulin resistant. Adipocytes also can produce 
adipokines such as leptin and adiponectin which have been proved as insulin sensitizers due 
to their ability to decrease triglycerides (TG) synthesis, to stimulate beta oxidation of fatty 
acids, and thus to enhance insulin action in both skeletal muscle and liver [17–19]. 
 
Genetically modified animals deficient in white adipose tissue usually have severe insulin 
resistance in liver and muscle [20]. Transplantation of normal fat tissue into white adipose 
tissue deficient mice restores the insulin sensitivity [21]. Mice with a knockout of the insulin 
receptor in muscle have normal glucose tolerance [22], whereas those with a knockout of the 
insulin-sensitive GLUT4 glucose transporter in adipose tissue have impaired glucose 
tolerance, apparently due to insulin resistance being induced in muscle and liver [23]. Other 
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recent Studies reported that obesity promotes inflammatory signals especially in the adipose 
tissues that disrupt insulin action and mediate insulin resistance [24]. Accordingly, the 
therapeutic targets of T2D will be preservation of beta cell structure and function, enhancing 
metabolic activity especially of the adipose tissues and decreasing lipid content in different 
tissues. In this review, we will focus on the possible roles of ghrelin, a natural ligand of the 
growth hormone secretagogue receptor type 1a (GHS-R1a), and hexarelin, a synthetic 
peptidyl GHS in the treatment of diabetes and diabetic-associated heart diseases. 
 
Growth Hormone Secretagogues (GHS) 
GHS are substances which stimulate the release of GH from the pituitary. They include the 
natural endogenous one, ghrelin, which is predominantly produced by A-like cells of the 
stomach from its precursor proghrelin [25] and synthetic peptidyl and non-peptidyl 
molecules. The ghrelin peptide is acylated to acylated ghrelin (AG) by the enzyme ghrelin-O-
acyltransferase (GOAT) [26]. AG is present in serum at a 2.5-fold lower concentration than 
unacylated ghrelin (UAG) [27]. UAG has been thought for a long time to be an inactive 
metabolite of AG [25, 27]. However, it is now recognized that UAG may exert 
physiologically relevant effects through an unidentified receptor. UAG can antagonize the 
effect of AG [28, 29]. However, in some cases UAG acts synergistically with AG [30] or 
have AG-independent effects [31]. UAG seems to oppose the effect of AG at the metabolic 
levels such as insulin secretion and food intake but cannot counteract it at the neuroendocrine 
levels like GH release, prolactin or adrenocorticotrophic response [27]. Most of the effects of 
AG appear to be mediated through activation of GHS-R1a, as the specific receptor 
antagonist, [d-Lys3]-GHRP-6 completely blocks the protective effects of ghrelin against 
oxygen–glucose deprivation insult [32]. In contrast, Baldanzi et al. reported that in 
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cardiomyocytes ghrelin exhibits an antiapoptotic effect through binding to a novel, 
unidentified receptor that is distinct from GHS-R1a [33]. 
 
The GHS-R is a G protein-coupled seven-transmembrane domain receptor and was initially 
identified as a receptor for small synthetic molecules GHS, such as hexarelin, L-692,429, 
GHRP-6, and MK-0677, all of which stimulate GH secretion from the pituitary [34, 35]. The 
GHS-R has two forms GHS-R1a and GHS-R1b. The GHS-R1a is the functionally active and 
signal transducing form of the GHS-R, whereas the GHS-R1b is devoid of high-affinity 
ligand-binding and signal transduction activities [36]. Expression of the GHS-R1a receptor 
was shown in the hypothalamus and anterior pituitary gland which is consistent with its role 
in regulating GH release [35, 37]. GHS-R1a receptor is also expressed in many peripheral 
organs. GHS-R1a receptor mRNA was shown in the stomach and intestine [38], pancreas 
[34], kidney [39], heart, and aorta [40], as well as in different human pituitary adenoma and 
various endocrine neoplasms of different organs [41–43]. These findings indicate that ghrelin 
and synthetic GHS have many functions other than the control of GH release. Ghrelin and 
synthetic GHS are potent stimulators of GH release [44–46]. However, the activity of both 
ghrelin and synthetic GHS is not fully specific for GH and includes stimulatory effect on both 
lactotroph and corticotroph secretion [46, 47]. Ghrelin enhances Appetite and increases food 
intake in humans [48] and animals [49] either injected centrally [50, 51] or peripherally [48, 
52]. Ghrelin has been shown to have many protective effects on the cardiovascular system 
[53–56]. Ghrelin also has been proved to be a potent anti-inflammatory mediator both in vitro 
and in vivo in lymphocytes, monocytes, and dendritic cells and promoting IL-10 expression 




The synthetic, peptide GHS are also known as growth hormone-releasing peptides (GHRPs). 
GHRP-6 was the first hexapeptide shown to release GH in vivo, especially in humans after 
oral administration with low bioavailability and short-lasting effect [58, 59]. Recently, 
heptapeptide, GHRP-1, and two other hexapeptides, hexarelin and GHRP-2, have been now 
synthesized [60, 61]. Hexarelin (His-d-2MeTrp-Ala-Trp-d-Phe-Lys-NH2) differs from 
growth hormone-releasing peptides GHRP-6 by having a methyl group in position 2 of the 
DTrp [62]. This minor modification was beneficial, making hexarelin more stable and longer 
acting in vivo [63]. Hexarelin is more potent than GHRP-6 as a GH releaser [64–66]. 
Hexarelin has many physiological actions independent of growth hormone such as the 
protection against cardiac ischemia and impairment of vascular endothelium function in the 
hearts of GH-deficient rats [67, 68]. GHS-R1a seems to mediate the action of hexarelin. 
However, some studies have reported that the CD36 receptor mediates the action of hexarelin 
in the heart and mouse 3T3-L1 preadipocytes [69, 70]. Our review will concern on the 
functions of ghrelin and hexarelin in the protection, regeneration of beta cells, regulation of 
insulin release, glucose metabolism, and their possible uses in treatment of diabetes and heart 
diseases. 
 
Effects of ghrelin on pancreatic beta cells. 
Ghrelin has been shown to promote survival and inhibit apoptosis in many cell types. Ghrelin 
protected human endothelial cells against apoptosis caused by high glucose [71]. Treatment 
of 3T3-L1 preadipocytes with ghrelin inhibited adipocyte apoptosis induced by serum 
deprivation, induced cellular proliferation and differentiation to mature adipocytes. Ghrelin 
also increased the basal and insulin-stimulated glucose transport in theses adipocytes [72]. 
Ghrelin has been confirmed to have protective effects against different stressful factors 
including TNF-alpha [73] and doxorubicin [33]. Hexarelin is able to both increase cell 
8 
 
proliferation and protect adult rat hippocampal progenitor (AHP) cells from apoptosis and 
necrosis induced by growth factor deprivation [74]. Interestingly, ghrelin is recently shown to 
protect beta cells from apoptotic effect of saturated fatty acids [75]. It is obvious in many 
studies that prolonged exposure of isolated islets or beta cell lines to saturated fatty acids is 
associated with beta cell apoptosis [76–78]. The signaling pathways that regulate pancreatic 
beta cell apoptosis during lipotoxicity or the oxidative stress could be inactivation of 
phosphatidylinositol-3 kinase/protein kinase B (PI3K/AKT), sustained c-Jun N-terminal 
kinase (JNK) activation, phosphorylation of forkhead box protein O1 (Foxo1) at serine and 
threonine sites distinct from those phosphorylated by AKT, enhancing the nuclear retention 
of Foxo1 [79, 80]. However, it is unclear whether inhibition of AKT or activation of JNK 
precedes inhibition of Foxo1 nuclear translocation or if there is a crosstalk between 
PI3K/AKT activation and JNK inhibition. Therefore, further studies are needed to clarify the 
mechanisms of these signaling molecules in the protection of beta cells from apoptosis. 
Ghrelin has been shown to exert the antiapoptotic effects on beta cells via G protein-coupled 
receptor/CAMP/PKA, activation of PI3K/AKT, and extracellular signal-regulated kinase 
(ERK) [81, 82] (See Fig. 1). Wang et al. has demonstrated that ghrelin inhibits the apoptosis 
and promotes beta cell proliferation through nuclear exclusion of Foxo1 and inhibition of 
endoplasmic reticulum (ER) stress pathway [83].  
 
AG increased insulin expression and secretion and PDX1 mRNA in the pancreas of STZ-
treated rat [84]. PDX1 is a transcriptional factor which is essential for insulin transcription 
and maintenance of beta cell mass [85]. Similarly, UAG and obstatin, which is encoded in the 
same gene as ghrelin, increased islet area, islet number, and beta cell mass and insulin and 
PDX1 mRNA compared to the pancreas of STZ-treated rat and also increased the expression 
of antiapoptotic gene, BCL-2 [86]. Both UAG and AG induced cell survival and protection 
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against apoptosis in isolated human islets of Langerhans [82, 87]. The insulin-positive beta 
cells in these islets expressed GHS-R1a, explaining the mechanism of action for AG. 
However, the radiolabelled binding studies for UAG suggest that these islets also express 
UAG and AG binding sites that are probably not the classical GHS-R1a [82]. Therefore, the 
effects of UAG and AG may also occur via mechanisms independent of the GHS-R1a, likely 
mediated by specific AG and UAG binding sites. Taken together, these findings indicate that 
the binding sites of AG and UAG are different or may be some GHS-R subtypes could 
recognize and bind ghrelin independently of its acylation. However, the downstream 
signaling mechanisms in protecting beta cells may be the same for both peptides via the 
















































































islet cell proliferation and survival (GHS-R1a GH secretagogue receptor type 1a, 
PI3K phosphatidylinositol 3-kinase, MAPK Mitogen-activated protein kinases 
(MAPK), ERK1/2 extracellular signal-regulated kinase 1/2, NO nitric oxide, PDX1 
pancreatic and duodenal homeobox-1, JNK Jun-N-terminal kinase, Foxo1 
Forkhead transcription factors of the FoxO family). 
 
 
 Moreover, some studies have reported the potential roles of ghrelin in the regeneration of 
beta cells. Beta cell regeneration is an alternative strategy to replace islets transplantation 
especially with the shortage of pancreatic donors [88]. Pancreatic regeneration requires 
expansion of beta cells through beta cell neogenesis, dedifferentiation of acinar cell to beta 
cells, and proliferation of progenitor beta cells [89, 90]. Various agents have been studied to 
increase pancreatic regenerative capacity; the most important ones are glucagon-like peptide 
1, actin, members of the transforming growth factor beta family, and the polypeptide growth 
factor beta [91–93]. Interestingly, ghrelin has been reported to influence the embryologic 
development of the pancreas and to regulate insulin secretion [94, 95]. Rats received 90 % 
pancreatectomy (surgical removal of 90 % of pancreas) were shown to have severe 
hyperglycemia and decreased beta cell mass and insulin levels. AG administration strongly 
reduced glucose levels, increased insulin-producing beta cell number, and insulin secretion. 
On the contrary, ghrelin receptor antagonist [d-Lys3]-GHRP-6 administration in these 
pancreatectomized rats worsens glucose levels and decreases beta cell mass [96]. AG, UAG, 
and obstatin counteracted the hyperglycaemia and improved plasma and pancreatic insulin 
levels, which were reduced by the STZ compound in newborn rats treated with STZ [84]. 
UAG and Obstatin increased islet area, islet number, and beta cell mass with respect to STZ 
treatment alone [86]. These findings strongly suggest that beta cells damaged by STZ 
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administration during the neonatal stage or reduced by pancreatectomy can be regenerated or 
replicated following ghrelin treatment. This ability of GHS to regenerate beta cells may be 
supported by previous studies that have shown the regeneration effect of GH itself on the 
pancreas [97]. In conclusion, these findings provide evidence that GHS may function as a 
survival and regenerative factor for beta cells and offer a new perspective on the potential 
role of these peptides in diabetes. 
 
Effects of ghrelin and hexarelin on insulin secretion and glucose homeostasis 
The role of the ghrelin in the regulation of insulin secretion and insulin action remains a 
controversial topic. Ghrelin is reported to either inhibit or stimulate insulin secretion in 
animals (as shown in Table 1) and humans (as shown in Table 2). The discrepancies of 
ghrelin effects in different studies may be due to the following reasons: (1) the implications 
of ghrelin on insulin secretion and glucose metabolism could be different in different energy 
states like fasting, fed, obese, and diabetic, (2) Ghrelin, GHS-R, and GOAT are all expressed 
in pancreatic islets, suggesting a role for locally expressed ghrelin that could be different 
from that of the systemic ghrelin in the regulation of insulin release, (3) some of effects of 
ghrelin are independent of GHS-R1a and this highlight the complexity of the ghrelin-
signaling pathway. This can be indicated by the paradoxical effects of ghrelin ablation and 
GHS-R ablation in ob/ob mice [98], (4) the controversy could be also due to differences in 
experimental design (different doses, different times of observation, mode of injection, in 
vitro versus in vivo experiments, etc.). This is obvious in one study that tested the effect of 
different concentration of ghrelin on insulin release. The study showed that ghrelin 
concentrations in the physiological range had no effect on glucose-stimulated insulin 
secretion (GSIS), while low ghrelin concentrations inhibited and high stimulated it [99]. The 
insulin response to glucose was enhanced in the presence of a high ghrelin concentration. 
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Another study showed that the subcutaneous administration of ghrelin induced relatively 
specific GH release and enhanced cardiac performance in humans without significant adverse 
effects [99], and (5) long-term versus short-term actions of the peptide. In one study, the 
stimulatory action of ghrelin on insulin levels in rats was observed at 15 min but not at 5 min 
after ghrelin administration [100]. Therefore, the net effect on insulin sensitivity of 
manipulation of the ghrelin system still remains to be determined, although the overall 
systemic effects suggest promoting insulin resistance.  
 
AG levels may be an important predictor of the glucose control under physiological 
conditions [101]. Ghrelin clearly stimulated insulin-mediated glucose disposal, an 
observation that was consistent with enhanced 2-deoxy-d-[3H]glucose (2DG) uptake in 
muscle and adipose tissue during hyperinsulinemia in ghrelin-treated animals [102]. In 
contrast, ghrelin hampered inhibition of endogenous glucose production by insulin. 
Furthermore, simultaneous administration of UAG abolishes the inhibitory effect of ghrelin 
on hepatic insulin action [102]. AG and UAG have been proposed to have opposite effects on 
glucose metabolism, which suggests a potentially significant influence of them on glucose 
metabolism [103]. Transgenic mice overexpressing ghrelin under the rat insulin II promoter 
had a pancreatic UAG content that was 1,000 times higher than the control mice. Such mice 
showed reduced GSIS and lower blood glucose levels and triglyceride levels during insulin 
tolerance test [104]. The suppression of insulin secretion is likely due to the enhancing effect 
of UAG on insulin sensitivity. Insulin secretion from isolated islets was instead 
indistinguishable from that of non-transgenic mice. These results imply that UAG, opposite 
to AG, increases insulin sensitivity. Gauna et al. reported that administration of AG in 
humans reduces insulin sensitivity, whereas the combination of AG plus UAG strongly 
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improves insulin sensitivity [105]. Another studies reported that the dysregulation of 
AG/UAG ratio could play a role in pathogenesis of insulin resistance and diabetes [106, 107]. 
 
Ghrelin influences insulin and glucose homeostasis through a range of central and peripheral 
GHS-R-mediated mechanisms. Glucose and insulin also influence ghrelin secretion [108, 
109]. Ghrelin influences glucose homeostasis centrally through medial hypothalamus. Re-
expression of GHS-R in hypothalamic neurons expressing agouti-related peptide (AgRP) of 
adult GHS-R-null mice restores the orexigenic response to administered ghrelin and lowered 
blood glucose levels during caloric restriction [110]. This normalized glucoregulatory 
response was associated with glucagon rises and hepatic gluconeogenesis, indicating that 
hypothalamic arcuate-expressing agouti-related peptide (AGRP) neurons are responsible for 
the orexigenic effects and the central effects of ghrelin on glucose homeostasis. The effect of 
hexarelin on blood insulin, glucose, and in general on type 2 diabetes mellitus has not been 
studied well yet. In one study, obese and lean male rats of the Zucker strain were treated with 
hexarelin (80 μg/kg, b.i.d., s.c.) or saline (1 ml/kg, b.i.d., s.c.) for 30 days [111]. The results 
showed an increase in plasma insulin concentration in the obese rats treated with hexarelin. 
Obese rats treated with saline had plasma glucose concentrations similar to those found in 
lean animals. Treatment with hexarelin increased plasma glucose concentrations in obese rats 
but not in lean rats. One possibility of these findings may be related to the ability of hexarelin 
to stimulate the hypothalamic–pituitary–adrenal (HPA) axis [112, 113]. However, the 






Table 1. The in vivo and in vitro effects of ghrelin on insulin secretion and glucose 
homeostasis in animals. 




Rat pancreatic islets AG 10-12 M  in vitro Increased GSIS. [114] 
Isolated pancreas from 
normal and STZ treated rats 
AG 10-9 M  in vitro Increased insulin release from 
the pancreas of normal and 
diabetic rats.  
 
[115] 
Wistar rats with 90% 
pancreatectomy 
AG *I.P. (10 nM /Kg/day) 
in the first postoperative 
day. 
Increased plasma insulin from 
the 15th postoperative day 
and reduce plasma glucose. 
[96] 
STZ-treated neonatal rats. AG *S.C. (100 μg/kg/ day) for 
7 days (from day 2 to 8) 
after birth. 
No changes in blood glucose 
or insulin levels between the 
STZ and STZ/Ghrelin groups. 
Significant increase in insulin 
expression and insulin mRNA 







100 nM in vitro Increased GSIS. UAG being 
more potent than AG at 
raising insulin levels. 
[82] 
STZ-treated neonatal rats AG or UAG   S.C. (100 μg / kg, twice 
daily), from day 2 to 8 
after birth. 
AG or UAG reduced glucose 
levels, restored plasma 




GH-deficient little mice and 
control wild mice 
AG or UAG I.P. (1 and 10 nM / kg). 
 
AG decreased insulin and 
elevated blood glucose levels. 
UAG failed to significantly 
alter blood glucose levels. 
AG at 10 nmol/l, but not 0.1 
nmol/l and 1 pmol/l, 
decreased GSIS  in islets. 
[116] 
Perfused pancreas from 
male wister rats & 
isolated islets from male 
ghrelin knockout and 
wild-type mice 
AG or UAG 10 nM in vitro AG suppressed both phases 
of GSIS.  
UAG has no effect. 
Ghrelin knockout mice 
display increased insulin and 
decreased glucose levels. 
Increase GSIS from isolated 
islets of ghrelin knockout 
mice. 
[117] 
Min6 cells with 
overexpression of UCP-2 
AG 10 nM in vitro Inhibited GSIS. [118] 
Isolated rat pancreas  AG 10 nM in vitro No change of basal insulin 
release but markedly 
inhibited GSIS and insulin 
release elicited by 1 mM 
carbachol. 
[119] 
Isolated rat islets & INS-
1E cells 
AG 10 nM for isolated islets & 
 
Inhibited GSIS in both the 




1 nM for INS-1E cells  
 
INS-1E cells AG (rat, 
human  or * 
Dap 
octanoylate
d human)  
or UAG (rat 
or human) 





*I.V. (25 nmol) into the 
jugular vein. 
Increased insulin significantly 
at 15 and 60 min after the 
injection, compared with 
control. 
[100] 
Female C57BL/6J mice & 
isolated islets from mice 
AG I.V. (50, or 150 nM/kg) 
with glucose at the dose of 
1 g/kg in a tail vein and  
0.01 - 1 nM for the 
isolated islets 
Inhibited plasma insulin. No 
effect on insulin sensitivity. 




*Adult male WT, ghrelin−/−, 
and Ghsr−/− mice 
  Lowered insulin 
concentrations in both 
ghrelin−/− and Ghsr−/− mice 
compared with WT mice 
during the postabsorptive 
state. 




between the three groups.  
*I.P.: intraperitoneal injection. 
*S.C.: subcutaneous injection. 
*I.V.: intravenous injection. 
*Dap-octanoylated human ghrelin (DapAG), a ghrelin molecule where the octanoyl group on the third serine residue is stabilized by a α- 
and β-diaminopropanoic acid. 





Table 2. The effects of ghrelin on insulin secretion and glucose homeostasis in humans. 
Morbidly obese non-
diabetic subjects 
UAG or UAG 
+AG 
I.V.: UAG: 200 ug 
or UAG 100 ug + 
AG 100 ug for 4 
days 
UAG +AG decreased insulin 
and no effect on blood glucose. 
UAG had no effect on blood 
glucose or plasma insulin. 
[124] 
Healthy subjects AG  AG (0.3, 0.9 and 
1.5 nmol/kg/h) or 
saline was infused 
for more than 65 
min 
AG decreases GSIS and worsens 
intravenous glucose tolerance in 
healthy humans. 
[125] 
Obese and normal 
women 
AG I.V. 1μg/kg Increased glucose and reduced 
insulin in obese women and 
increased glucose but not insulin 




AG I.V. 1μg /kg  Inhibited insulin and increased 
glucose levels. Ghrelin did not 
modify both glucose and insulin 




AG  or UAG I.V. 1 μg /kg AG decreased  in insulin levels 
and increased in blood glucose 





AG or AG + 
UAG 
AG: 1 μg/kg 
UAG: 1 μg/kg 
AG and to a lesser extent UAG 
induced significant 
hyperglycemia. No increase in 




administered 15 min before the 
administration of AG.  AG + 
UAG seemed to lower serum 
glucose levels significantly. 
AG + UAG induced a significant 





*EHC: AG  
 
AG: I.V. 5 pmol/kg 
per minute 5 h 
pancreatic clamp 
Decreased insulin sensitivity [129-131] 
Healthy humans EHC: AG 5 h 
(intramuscular) 
6.25 mg/l Increased insulin sensitivity [132] 
*OGTT: Oral glucose tolerance test 








Effects of ghrelin and hexarelin on adipose tissue. 
The effect of ghrelin on adipose tissue has also been reported. Ghrelin increased the insulin-
stimulated deoxyglucose uptake in isolated white adipose tissue from epididymal fat at 
concentration of 1,000 nM compared to 0.1 nM insulin alone. Ghrelin increased slightly the 
glucose uptake at 100 nM without statistical significance [133]. AG did not increase the 
deoxyglucose uptake in peri-renal adipocytes, which does not express GSH-R1a. UAG had 
no effect on insulin-stimulated glucose uptake. The dose of ghrelin in this study was above 
the physiological plasma concentration of ghrelin which could be explained by the difference 
in the effect and the dose of local and systemic ghrelin. The local ghrelin concentrations in 
adipose tissues may be considerably higher than those in the circulation and systemic ghrelin 
could be less important in the modulation of glucose uptake than those found locally. Ghrelin 
enhanced insulin-stimulated glucose uptake in adipocyte cell line, 3T3-L1 [72]. On the 
contrary, Ott et al. reported that ghrelin pre-treatment had no effect on insulin-stimulated 
glucose uptake in an immortalized brown adipocyte cell line [134]. Consequently, ghrelin 
appears to directly potentiate adipocyte insulin-stimulated glucose uptake in selective 
adipocyte populations and may play a role in adipocyte regulation of glucose homeostasis. 
Also, ghrelin regulate cholesterol efflux in macrophages through a GHS-R1a/PPAR-γ-
dependent pathway [135]. Interestingly, these studies showed that PI3K/AKT pathway is 
mediating PPAR-γ activation by ghrelin which is the same pathway that mediates the 
antiapoptotic effects of ghrelin on various cells. 
 
The potential effects of hexarelin on lipid metabolism have been studied. Hexarelin through 
binding to CD36 receptor induced an increase in thermogenic coactivator PGC-1α and 
uncoupling protein-1 (UCP-1) in 3T3-L1 adipocytes as well as in epididymal fat of treated 
mice, indicating increased fatty acids metabolism in the white fat in response to hexarelin 
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[70]. Hexarelin treatment in obese rats significantly decreased plasma cholesterol but not 
triglyceride levels [111]. In another study, apolipoprotein E-null mice maintained on a long-
term, high-fat, and high-cholesterol diet, a condition known to cause atherosclerosis, showed 
a significant regression in atherosclerotic lesions when treated with hexarelin compared to 
saline-treated controls [136]. This study demonstrated the activation of the PPAR-γ- liver X 
receptor (LXRα)-ATP-binding cassette transporters (ABC) metabolic cascade could be the 
signaling pathway for the action of hexarelin to cause the macrophages to mobilize excess 
cholesterol into the HDL cholesterol reverse pathway. These beneficial effects of hexarelin 
were observed under conditions in which GH was not upregulated, and similar effects 
observed in mice treated by EP80317, a hexarelin derivative with no GH release activity, 
supporting a GH-independent role for hexarelin [137]. 
 
These effects of hexarelin derived from enhanced expression of PPAR target genes, resulting 
in a thermogenic-like profile. PPAR-γ is considered a master regulator of fatty acid 
metabolism in fat through its direct role in regulating the expression of a broad range of genes 
involved in fatty acid and glucose metabolism [138]. Among the genes upregulated by 
PPAR-γ, genes related to fatty acid uptake (fatty acid transport protein FATP, CD36), 
glucose uptake (GLUT4), β-oxidation (acyl-CoA dehydrogenase, carnitine 
palmitoyltransferase CPT-1, acyl-CoA oxidase), gluconeogenesis (phosphoenolpyruvate 
carboxykinase PEPCK), and lipid storage (adipophilin). PPAR-γ also plays a central role in 
coordinating the macrophage response to lipid loading through a transcriptional cascade 
involving LXRα and the ABC transporters A1 and G1 [139, 140]. Similarly, PPAR-γ 
agonists of the thiazolidinedione family were shown to exert beneficial anti-diabetic and anti-
atherosclerotic actions by promoting activation of the PPAR-γ-LXRα-ABC pathway and 
cholesterol efflux [141, 142]. Consequently, we suppose that ghrelin or hexarelin by 
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modulation of PPAR-γ activity could enhance insulin sensitivity, regulate cholesterol 
metabolism in macrophages, and prevent atherosclerotic vascular lesion progression. 
Recently, hexarelin also inhibited cholesterol synthesis in liver cells through the activation of 
the adenine monophosphate-activated protein kinase (AMPK) pathway, reduction of 3-
hydroxy-3-methylglutaryl-CoA reductase (HMGR), and increase recruitment of the anchor 
proteins insulin-induced genes (Insig-1 and Insig-2) in the liver cells [143]. HMGR is the 
rate-limiting enzyme in the cholesterol biosynthesis pathway. These findings support that 
CD36 and its ligands such as hexarelin play a role in regulating AMPK activity fatty acid 
metabolism and reverse cholesterol transport. 
 
Ghrelin and hexarelin promote mitochondrial activity and biogenesis 
The cause of apoptosis and failure of beta cell that occur during T2D are still unknown. 
However, mitochondria may play a role in regulating apoptosis and insulin secretion [144, 
145]. Many studies have reported the beta cells in T2D do not sense glucose properly and 
consequently do not release enough amounts of insulin. The increased glucose and fatty acids 
could cause beta cell mitochondrial damage, leading to decreased ATP due to increase of 
mitochondrial membrane potential and production of ROS [146] (as shown in Fig. 2). Beta 
cells are susceptible to oxidative stress due to the weak expression of antioxidative enzymatic 
defenses, e.g., catalase and superoxide dismutase (SOD). Increased ROS can cause leakage of 
protons into the mitochondrial matrix, leading to decreased ATP production, and thus 
reduced GSIS [147]. Uncoupling protein 2 (UCP-2) modulates coupling efficiency and may 
regulate GSIS [148]. A small reduction in the mitochondrial membrane potential induced by 
mild uncoupling has a significant effect in attenuating ROS production [149]. However, the 





It was interesting to observe that hexarelin and ghrelin enhanced mitochondrial structure and 
metabolism by upregulating many genes related to the mitochondrial metabolism of glucose 
and fatty acids [70]. More specifically, the upregulation of the genes which encode acetyl 
CoA acyl transferase, CPT-1, and several subunits of the ATP synthase and cytochrome c 
oxidase complexes may suggest an increased fatty acid metabolism through the 
mitochondrial oxidative phosphorylation pathway. The mitochondria of hexarelin-treated 
3T3-L1 adipocytes showed an intense and highly organized cristae formation that spanned 
the entire width of mitochondria compared to that in untreated cells as shown by the electron 
microscopy [70]. Ghrelin also exerts a protective effect against H2O2-induced apoptosis in 
H9c2 rat cardiomyocytes by reducing the proapoptotic protein Bax and increasing Bcl-2 
expression, accompanied by decreasing activation of caspase-9 and caspase-3 [150]. These 
results demonstrate that the antiapoptotic effect of ghrelin is probably caused by decrease 
H2O2-induced mitochondrial stress and by blocking activation of NF-κB. The transcription 
factor NF-κB is a critical signaling molecule in oxidant stress responses. UCP-2 mRNA 
expression was downregulated in INS-1 beta cell by ghrelin in the presence of 26.4 mM 
glucose [151]. Other studies showed that ghrelin decreased oxidative injury in the stomach 






























































































































products (AGEs) and collagen [160, 161]. Functionally, there are diastolic abnormalities 
which have been suggested as early functional abnormalities of diabetic CM [162, 163]. The 
cardioprotective effects of hexarelin and ghrelin have been well investigated. Many studies 
have shown their beneficial effects on the cardiovascular system such as protection against 
cardiac ischemia, cardiac fibrosis, improving cardiac function, and decreasing peripheral 
resistance after myocardial infarction (MI) in animals [164–166] and humans [167]. Our 
group showed that treatment of spontaneously hypertensive rats (SHRs) with hexarelin for 5 
weeks from an age of 16 weeks significantly reduced cardiac fibrosis in SHRs by decreasing 
interstitial and perivascular myocardial collagen deposition and myocardial hydroxyproline 
content and reducing mRNA and protein expression of collagen I and III in SHR hearts [168]. 
In addition, hexarelin treatment significantly attenuated left ventricular (LV) hypertrophy, LV 
diastolic dysfunction, and high blood pressure in SHRs. So, our data demonstrate that 
hexarelin reduces cardiac fibrosis in SHRs, perhaps by decreasing collagen synthesis and 
accelerating collagen degradation [168]. 
 
Ghrelin and hexarelin showed protective effects on cardiac ischaemia. Administration of 
ghrelin in vitro to ischaemia/reperfusion (I/R) rat hearts was shown to reduce the infarct size 
through the activation of PKC, and these effects were likely initiated by the binding of 
ghrelin to its receptor, GHS-R1a [169]. Pre-administration of ghrelin in vivo greatly 
ameliorated the damaged heart function, attenuated myocardial injury, and apoptosis through 
inhibition of ER stress [170]. The role of hexarelin on the protection against cardiac ischemia 
has been reported earlier [67, 68, 171]. Rats pre-treated with ghrelin or hexarelin for 7 days in 
vivo prior to in vitro I/R injury showed an improvement in cardiac function [172]. A single 
dose of oral hexarelin treatment at the very acute phase after MI has protective effects on 
chronic cardiac function [173]. Aragno et al. also showed that obestatin, which is encoded by 
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the same gene for ghrelin, protected STZ-caused myocardial dysfunction [174]. Our group 
has confirmed the protective effect of hexarelin and ghrelin on cardiac ischaemia [164]. 
Ghrelin (10 nM) or hexarelin (1 nM) was administered in the perfusion solution of isolated 
hearts before or after ischemia for 10 min. It was found that relative sarcomere shortening 
was significantly reduced after I/R and exhibited a reduction in both the amplitude and rising 
rate of intracellular calcium ([Ca2+]i) transients but increases in cytoplasmic [Ca2+]. The 
alternation in [Ca2+]i transients and cytoplasmic [Ca2+] which occurs during the cardiac 
ischemia and reperfusion is due to reduction of sarcoplasmic reticulum (SR) Ca2+ ATPase 
and Na/K ATPase activities or due to increased oxidative stress which occurs during the 
reperfusion which leads to subsequent damage to the plasma and SR membranes and further 
increases in cytoplasmic Ca2+. Pre- and post-treatments with ghrelin and hexarelin protected 
freshly isolated mouse ventricular cardiomyocytes against these negative effects of I/R. They 
resulted in normal cardiomyocytes contractility, normal amplitude, and rising rate of [Ca2+]i 
transients in the cardiomyocytes during an in vitro I/R injury, which could be attributed to 
normalized SR Ca2+ ATPase activity and SR Ca2+ content [164]. 
 
To compare the effect of ghrelin and hexarelin on cardiac function after infarction MI, 
ghrelin-knockout mice were used to show whether hexarelin could compensate for the ghrelin 
deficiency [175]. The results showed that hexarelin-treated mice had better cardiac function 
than ghrelin-treated mice, as indicated by the higher absolute values of percent of the ejection 
fraction (EF), peak rate of pressure rise (dP/dt max) and dP/dt min, fractional shortening 
(FS), preload-adjusted maximal power (PAMP), and maximal elastance (Emax). Hexarelin 
and ghrelin treatments also significantly reduced collagen volume fraction in the non-
infarcted LV walls and plasma atrial natriuretic peptide levels than vehicle administration 
[175]. These stronger effects of hexarelin was also confirmed by another study in which 
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hypophysectomized rats were treated in vivo for 7 days with either ghrelin (320 g/kg) or 
hexarelin (80 g/kg), and then their hearts were subjected in vitro to the ischemia and 
reperfusion procedure [172]. Ghrelin was far less effective than hexarelin in preventing 
increases in LV end-diastolic pressure (15 and 60 % protection for ghrelin and hexarelin, 
respectively), coronary perfusion pressure (10 and 45 % reduction), and release of creatine 
kinase in the heart perfusate (15 and 55 % reduction). The effects of hexarelin were mediated 
largely by interactions with CD36 in the heart and to a lesser extent by GHS-R. However, 
other studies reported that ghrelin and hexarelin had similar effects [176]. 
 
In addition, AG and UAG also exert antiapoptotic effects on mouse and rat cardiomyocytes 
by acting on MAPK and PI3K/AKT pathways [33]. Similarly, our studies have confirmed the 
cardioprotective role of hexarelin in I/R models of hearts from mice [164]. GHS can preserve 
the electrophysiological properties of cardiomyocytes after I/R and inhibit cardiomyocyte 
apoptosis and promote cell survival by modification of MAPK pathways through activating 
GHS-R1a [176]. Hexarelin also showed a protective role on angiotensin II (ANG II)-induced 
apoptosis of isolated cardiomyocytes from neonatal rats [177]. Administration of hexarelin 
significantly decreased ANG II-induced apoptosis and DNA fragmentation and increased 
cardiomyocyte viability via inhibiting the increased caspase-3 activity and BAX expression 
and by increasing the expression of BCL-2. GHS-R mRNA was abundantly expressed in 
cardiomyocytes and was upregulated after administration of hexarelin. 
 
Recently, some studies have reported that the beneficial effect of ghrelin on the 
cardiovascular system might be mediated by modulation of cardiac autonomic nerve activity. 
Ghrelin has been shown to suppress sympathetic activity and to decrease blood pressure 
through mechanisms involving the central nervous system [178, 179]. The beneficial effects 
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of ghrelin were accompanied by the suppression of MI-induced increase of heart rate and 
plasma norepinephrine concentration [180]. These effects of ghrelin decreased with atropine 
pre-treatment or vagotomy. Ghrelin exerted antiarrhythmic effects in rats during acute MI via 
modulation of vagal activity by showing increased high-frequency (HF) component as an 
index of parasympathetic activity and decreased low-frequency (LF)/HF ratio as an index of 
sympathetic activity and restoration of phosphorylated connexin-43 protein levels [181]. 
 
As connexin-43-deficient mice have been reported to be markedly susceptible to ischemia-
induced ventricular arrhythmias [182]. Other studies have been proposed to explain the 
reduction in blood pressure after ghrelin administration, including vasodilation via 
endothelium activation or a direct effect on vascular smooth muscle cells [183, 184]. Ghrelin 
also inhibited post-infarct myocardial remodeling, while improving cardiac function through 
its anti-inflammatory effects as shown by decreased mRNA and protein levels of interleukin-
1beta and tumor necrosis factor-alpha [185]. 
 
Clinical studies in human with growth hormone deficiency (GHD) suggested that patients 
with either ischemic or non-ischemic CM might benefit from GHS therapy, mainly from 
reduction of LV maladaptive remodeling and cardiomyocyte loss. In healthy volunteers and 
in patients with GHD, an acute administration of hexarelin (2 µg/kg) elicited a short-term 
increase in contractility and LV ejection fraction in a GH-independent manner [186]. Similar 
results were observed in patients with ischemic CM but not with dilated CM [187]. Studies 
with ghrelin showed an improved cardiac function following acute administration, although 
this effect was associated with a dose-dependent increase in GH [188]. Also, a short-term 
infusion of ghrelin (0.1 µg/kg/min60 min) decreased mean arterial pressure and increased 
cardiac and stroke volume index, which may be related to a reduced systemic vascular 
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resistance in healthy volunteers and in patients with heart failure. The cardiovascular effects 
of GHS could be through GHS-R1a in the heart and the blood vessels or through CD36 that is 
a specific cardiac receptor for hexarelin [189]. 
 
Conclusions 
The exact mechanisms by which GHS promote their metabolic response are not fully 
understood. However, it becomes clear that interacting with GHS-R1a and/or other receptors 
induces profound changes in metabolic activities of target tissues, especially regarding 
PPAR-γ-downregulated events. These metabolic effects besides the proliferative, 
regenerative, and antiapoptotic effects of GHS on beta cells represent a promising avenue in 
the treatment of diabetes and diabetic related heart diseases. 
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